ATE480566T1 - Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs - Google Patents

Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs

Info

Publication number
ATE480566T1
ATE480566T1 AT99925216T AT99925216T ATE480566T1 AT E480566 T1 ATE480566 T1 AT E480566T1 AT 99925216 T AT99925216 T AT 99925216T AT 99925216 T AT99925216 T AT 99925216T AT E480566 T1 ATE480566 T1 AT E480566T1
Authority
AT
Austria
Prior art keywords
prostate cancer
treating prostate
immunotherapeutic composition
immunotherapeutic
composition
Prior art date
Application number
AT99925216T
Other languages
German (de)
English (en)
Inventor
Beatrice Leveugle
Ragupathy Madiyalakan
Antoine Noujaim
Birgit Schultes
Original Assignee
Quest Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmatech Inc filed Critical Quest Pharmatech Inc
Application granted granted Critical
Publication of ATE480566T1 publication Critical patent/ATE480566T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99925216T 1998-06-15 1999-06-15 Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs ATE480566T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
ATE480566T1 true ATE480566T1 (de) 2010-09-15

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99925216T ATE480566T1 (de) 1998-06-15 1999-06-15 Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs

Country Status (9)

Country Link
US (3) US6881405B2 (enExample)
EP (1) EP1085905B1 (enExample)
JP (1) JP2002518347A (enExample)
AT (1) ATE480566T1 (enExample)
AU (1) AU768002B2 (enExample)
CA (1) CA2328504A1 (enExample)
DE (1) DE69942742D1 (enExample)
IL (1) IL139700A (enExample)
WO (1) WO1999065523A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
CZ302801B6 (cs) 1999-01-13 2011-11-16 Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
IL152747A0 (en) * 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2003086041A2 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
WO2004035003A2 (en) * 2002-10-17 2004-04-29 Altarex Medical Corporation Therapeutic adjuvant
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009126817A2 (en) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Ige antibodies for the treatment of cancer
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
DE3650139T2 (de) 1985-07-05 1995-03-09 Hutchinson Fred Cancer Res Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz.
EP0234122A3 (en) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
ATE145727T1 (de) 1989-09-15 1996-12-15 Genetic Systems Corp Hybridoma ct43, das ein antikörper gegen ein mucinepitop von darmkrebs erzeugt
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
AU4086397A (en) * 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer

Also Published As

Publication number Publication date
DE69942742D1 (de) 2010-10-21
US20050202018A1 (en) 2005-09-15
EP1085905B1 (en) 2010-09-08
AU4159499A (en) 2000-01-05
US20020136715A1 (en) 2002-09-26
WO1999065523A1 (en) 1999-12-23
JP2002518347A (ja) 2002-06-25
US20090220493A1 (en) 2009-09-03
CA2328504A1 (en) 1999-12-23
EP1085905A1 (en) 2001-03-28
IL139700A0 (en) 2002-02-10
IL139700A (en) 2005-09-25
US7579445B2 (en) 2009-08-25
US6881405B2 (en) 2005-04-19
AU768002B2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE453405T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
BR9707819A (pt) Imunogenos peptidicos
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
EP1117842A4 (en) METHODS FOR CHOOSING TREATMENTS AGAINST PROSTATE CANCER OR FOR TREATING PROSTATE CANCER
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
FR12C0004I1 (enExample)
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
ATE335504T1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties